Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
AstraZeneca’s Imfinzi Shows Positive Results in Treating Small Cell Lung Cancer

AstraZeneca’s Imfinzi Shows Positive Results in Treating Small Cell Lung Cancer

Posted on July 1, 2019
Post Views: 790

AstraZeneca’s Imfinzi Shows Positive Results in Treating Small Cell Lung CancerAstraZeneca has unveiled some data that suggests early-stage treatments for small cell lung cancer and could help in improvement of survival rates. According to AstraZeneca, a combination of Imfinzi and standard chemotherapy could extend lives in phase 3 trial in patients who are newly diagnosed with small cell lung cancer. The result of survival benefit in Caspian trail was statistically significant and meaningful.

José Baselga, Executive Vice President, Oncology R&D said: “The Phase III CASPIAN results offer new hope for patients who are facing the devastating diagnosis of small cell lung cancer, and for whom new medicines are urgently needed. This is the first trial offering the flexibility of combining immunotherapy with different platinum-based regimens in small cell lung cancer, expanding treatment options.”

AstraZeneca said that the data from its Phase III Caspian study has showed that PD-L1 checkpoint inhibitor Imfinzi combined with platinum-based chemotherapy improved overall survival rates in first-line extensive-stage small cell lung cancer patients. Caspian will continue to the final analysis of OS for combination of dual immune checkpoint blockade with chemo.

SCLC accounts for about 15% of overall lung cancer cases. Also, AZ says it is the most aggressive type of lung cancer. Looking at the research results, Imfinzi is all set to compete against another PD-L1 checkpoint inhibitor, Roche’s Tecentriq. Tecentriq is an approved first-line ES-SCLC in combination with chemotherapy drugs carboplatin and etoposide.

Imfiniz is approved for Stage III non-small cell lung cancer in more than 45 countries includes US, Japan and EU, based on Phase III Pacific trial.

The information shared in this blog is for educational purposes only and is certainly not a substitute for medical advice.

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,324)
  • Lung Cancer: Symptoms and Treatment (5,655)
  • What is Non-Small-Cell Lung Cancer? (5,551)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • Study: Wildfire Smoke Exposure Affects Lung Cancer Survival June 2, 2025
  • Predicting Lung Cancer Risk with AI based Deep Learning Model May 26, 2025
  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
  • Privacy Policy
  • About Us
  • Sitemap
  • Contact Us
%d